Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

This study has been completed.
Genentech, Inc.
Information provided by (Responsible Party):
University of Pennsylvania Identifier:
First received: May 11, 2007
Last updated: January 31, 2013
Last verified: January 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2011
  Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)